Phase III MISSION trial
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer, EGFR status may help select patients who will benefit most
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer, EGFR status may help select patients who will benefit most
Debate at ESMO 2012 Congress focuses on whether there is enough evidence to start using aspirin to reduce the risk of colorectal cancer
Where are the most promising developments from first-in-human studies?
Landmark global survey reveals major shortcomings in many countries around the world
Promising new data from trials aimed at delaying resistance to BRAF inhibitors
Head-to-head study compares of crizotinib with standard chemotherapy in this patient group
Studies presented at ESMO 2012 highlight challenges of cancer prevention
Take a stroll down memory lane and check out the `hot´ topics from past ESMO congresses in Vienna
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.